Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study.
暂无分享,去创建一个
C. Treloar | P. Dietze | M. Stoové | P. Higgs | A. Marshall | E. Baldry | L. Lafferty | Kerryn Drysdale | S. Schroeder
[1] T. Rhodes,et al. Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. , 2022, The International journal on drug policy.
[2] C. Aitken,et al. High rates of resumption of injecting drug use following release from prison among men who injected drugs before imprisonment , 2022, Addiction.
[3] J. Rehm,et al. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study , 2022, BMC Public Health.
[4] C. Treloar,et al. "It's a revolving door": Ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success , 2022, International Journal of Drug Policy.
[5] J. Rich,et al. Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison. , 2022, The International journal on drug policy.
[6] Peter B. Jones,et al. Qualitative study of candidacy and access to secondary mental health services during the COVID-19 pandemic , 2022, Social Science & Medicine.
[7] Maria del Mar Quiroga,et al. Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). , 2021, International journal of epidemiology.
[8] F. Altice,et al. Multi-level implementation factors that influence scale-up of methadone maintenance treatment in Moldovan prisons: A qualitative study , 2021, Journal of Substance Abuse Treatment.
[9] C. Treloar,et al. Structural competency in the post-prison period for people who inject drugs: A qualitative case study. , 2021, The International journal on drug policy.
[10] F. Altice,et al. Decisional considerations for methadone uptake in Kyrgyz prisons: The importance of understanding context and providing accurate information. , 2021, The International journal on drug policy.
[11] C. Oldmeadow,et al. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings , 2020, Addiction.
[12] G. Horvath,et al. The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases , 2020, Harm Reduction Journal.
[13] S. Haw,et al. A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in PRISONS. , 2020, The International journal on drug policy.
[14] Joanne Neale,et al. ITERATIVE CATEGORISATION (IC) (PART 2): INTERPRETING QUALITATIVE DATA. , 2020, Addiction.
[15] S. Ward,et al. Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia. , 2020, Addiction.
[16] Christy K. Scott,et al. A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System. , 2020, The International journal on drug policy.
[17] S. Baggio,et al. The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons—Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids , 2020, Frontiers in Psychiatry.
[18] G. Dore,et al. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. , 2020, The International journal on drug policy.
[19] K. Seear,et al. "A spray bottle and a lollipop stick": An examination of policy prohibiting sterile injecting equipment in prison and effects on young men with injecting drug use histories. , 2020, The International journal on drug policy.
[20] P. Crits-Christoph,et al. Trust and respect in the patient-clinician relationship: preliminary development of a new scale , 2019, BMC psychology.
[21] S. Bonato,et al. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review , 2019, PLoS medicine.
[22] Graeme Henderson,et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action , 2019, The Lancet.
[23] T. Dobbins,et al. The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study , 2019, The Lancet. Public health.
[24] Nanor Minoyan,et al. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. , 2019, The International journal on drug policy.
[25] C. Aitken,et al. The Prison and Transition Health (PATH) Cohort Study: Study Protocol and Baseline Characteristics of a Cohort of Men with a History of Injecting Drug Use Leaving Prison in Australia , 2019, Journal of Urban Health.
[26] E. McGlynn,et al. A Framework for Increasing Trust Between Patients and the Organizations That Care for Them , 2019, JAMA.
[27] T. Douglas,et al. The Case against Forced Methadone Detox in the US Prisons , 2016, Public health ethics.
[28] Josephine G. Walker,et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis , 2018, The Lancet. Infectious diseases.
[29] T. Wild,et al. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia’s prisons , 2018, Harm Reduction Journal.
[30] Caroline C. Johnson,et al. Beyond the walls: Risk factors for overdose mortality following release from the Philadelphia Department of Prisons. , 2018, Drug and alcohol dependence.
[31] C. Treloar,et al. ‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures , 2018, Drugs: Education, Prevention and Policy.
[32] P. Webster. Canada reveals needle exchange programme in prisons , 2018, The Lancet.
[33] J. Lazarus,et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries , 2018, Harm Reduction Journal.
[34] F. Luciani,et al. Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. , 2018, The International journal on drug policy.
[35] C. Treloar,et al. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. , 2018, Drug and alcohol dependence.
[36] J. Leung,et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.
[37] J. Strang,et al. High risk of overdose death following release from prison: variations in mortality during a 15‐year observation period , 2017, Addiction.
[38] S. Fazel,et al. Substance use disorders in prisoners: an updated systematic review and meta‐regression analysis in recently incarcerated men and women , 2017, Addiction.
[39] K. Dolan,et al. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia , 2017, Drug and alcohol review.
[40] M. Farrell,et al. Yes, people can die from opiate withdrawal. , 2017, Addiction.
[41] F. Altice,et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia , 2016, The Lancet.
[42] C. Treloar,et al. The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High? , 2016, PloS one.
[43] Joanne Neale,et al. Iterative categorization (IC): a systematic technique for analysing qualitative data , 2016, Addiction.
[44] Kristian Mjåland. Exploring prison drug use in the context of prison-based drug rehabilitation , 2016 .
[45] C. Treloar,et al. Trust and people who inject drugs: The perspectives of clients and staff of Needle Syringe Programs. , 2016, The International journal on drug policy.
[46] R. Mattick,et al. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film. , 2016, Drug and alcohol review.
[47] Kristian Mjåland. The paradox of control: An ethnographic analysis of opiate maintenance treatment in a Norwegian prison. , 2015, The International journal on drug policy.
[48] J. Wong,et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial , 2015, The Lancet.
[49] E. Wood,et al. Withdrawal from methadone in US prisons: cruel and unusual? , 2015, The Lancet.
[50] C. Treloar,et al. Acquiring hepatitis C in prison: the social organisation of injecting risk , 2015, Harm Reduction Journal.
[51] C. Treloar,et al. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. , 2014, The International journal on drug policy.
[52] T. Dobbins,et al. Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study , 2014, BMJ Open.
[53] Victorian Ombudsman,et al. Investigation into deaths and harm in custody , 2014 .
[54] H. Hansen,et al. Structural competency: Theorizing a new medical engagement with stigma and inequality , 2014, Social science & medicine.
[55] C. Chew‐Graham,et al. A qualitative study of patient choices in using emergency health care for long-term conditions: the importance of candidacy and recursivity. , 2013, Patient education and counseling.
[56] L. Møller,et al. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. , 2012, Addiction.
[57] Barbara Toson,et al. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. , 2012, Addiction.
[58] J. Rich,et al. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. , 2018, Journal of opioid management.
[59] R. D. Bruce,et al. Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. , 2008, The International journal on drug policy.
[60] M. Dixon-Woods,et al. Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups , 2006 .
[61] Andrew Robinson,et al. Uncovering the Limits of Patient-Centeredness: Implementing a Self-Management Trial for Chronic Illness , 2005, Qualitative health research.
[62] Paul Farmer,et al. An Anthropology of Structural Violence1 , 2004 .
[63] Richard L Kravitz,et al. Patient trust in the physician: relationship to patient requests. , 2002, Family practice.